ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Health Services Research Poster I – ACR/ARP

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM
Abstract Number: 253
A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease
9:00AM-11:00AM
Abstract Number: 248
Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
9:00AM-11:00AM
Abstract Number: 257
Alcohol Use Hospitalizations in People with Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain Are Increasing: A Time-trends Study Using the U.S. National Data
9:00AM-11:00AM
Abstract Number: 269
Attitudes and Beliefs About Opioid Medications: Determining Treatment Use in Osteoarthritis
9:00AM-11:00AM
Abstract Number: 273
Bone Health in Lupus: Findings from the Southern California Lupus Registry
9:00AM-11:00AM
Abstract Number: 256
Chronic Musculoskeletal Pain and Its Initial Management in Children, Adolescents and Young Adults in the United States
9:00AM-11:00AM
Abstract Number: 245
Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015
9:00AM-11:00AM
Abstract Number: 259
Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty
9:00AM-11:00AM
Abstract Number: 255
Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers
9:00AM-11:00AM
Abstract Number: 267
Develop Risk Prediction Model and Drug Withdrawl Road Map Through Pattern Extraction and Data Mining: Create a Master Algorithm from the Smart System of Disease Management (SSDM)
9:00AM-11:00AM
Abstract Number: 276
Effectiveness of Screening by Nurse with Predetermined Questionnaire on Infections Before Administration of Intravenous Biologics in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 277
Efficacy of a Counselling Program to Promote Physical Activity in People with Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 249
Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity
9:00AM-11:00AM
Abstract Number: 275
Exercise Is Medicine® in Primary Care Practice: Provider Characteristics and Physical Activity Counseling for Patients with Arthritis, DocStyles, 2018
9:00AM-11:00AM
Abstract Number: 265
Frequency of Performing Anti dsDNA Antibody in an ANA Negative Patient with Clinical Suspicion of SLE in a Single Centre Trial Before and After the Publication of National Guideline
9:00AM-11:00AM
Abstract Number: 264
Gaps in Patient Safety Performance in Patients with Immunosuppressive Therapy: Results of Screening for Infections and Vaccination Status in a Large Real-life Cohort
9:00AM-11:00AM
Abstract Number: 247
Health Literacy, Adherence, and Quality of Life of Uveitis Patients
9:00AM-11:00AM
Abstract Number: 263
Health Professionals Agreed with Recommendations to Evaluate and Optimize Adherence to Disease-modifying Treatments, but Perceived Feasibility Was Lower: A Study of 357 Physicians and Health Professionals in France
9:00AM-11:00AM
Abstract Number: 258
Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus
9:00AM-11:00AM
Abstract Number: 261
Impact of Rheumatoid Arthritis on Outcomes of Atrial Fibrillation: Results for National Inpatient Sample
9:00AM-11:00AM
Abstract Number: 278
Improving a SLE-Quality Indicator Tool in an Outpatient Tertiary Care Setting
9:00AM-11:00AM
Abstract Number: 254
Interstitial Lung Disease Associated Health Care Resource Utilization and Cost in Rheumatoid Arthritis Patients in an Insured Population
9:00AM-11:00AM
Abstract Number: 268
LARS Study: Latin American Rheumatologist Survey
9:00AM-11:00AM
Abstract Number: 251
Long-term Financial Impact of Switching from Reference to Biosimilar Etanercept When Considering Short-term Formulary Management Costs in the US
9:00AM-11:00AM
Abstract Number: 266
Measuring Advanced/Extended Practice Roles in Arthritis and Musculoskeletal Care in Canada: Stand up and Be Counted Too (2)!
9:00AM-11:00AM
Abstract Number: 272
Osteoporosis Management Outcomes in a Southern California County Health System
9:00AM-11:00AM
Abstract Number: 270
Outcomes of a Fracture Liaison Service at an Academic Health Center
9:00AM-11:00AM
Abstract Number: 262
Outpatient Healthcare Utilization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1988-2016)
9:00AM-11:00AM
Abstract Number: 274
Participation in the Stanford University Chronic Pain Self-Management Program in a Population with a High Prevalence of Arthritis
9:00AM-11:00AM
Abstract Number: 244
Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
9:00AM-11:00AM
Abstract Number: 260
Rheumatoid Arthritis Associated with Longer Hospital Stays in Patients Admitted with Venous Thromboembolism: A Nationwide Analysis 2010-2014
9:00AM-11:00AM
Abstract Number: 246
Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus
9:00AM-11:00AM
Abstract Number: 250
Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US
9:00AM-11:00AM
Abstract Number: 252
Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 271
Who Prescribed Which Osteoporosis Medication to Whom

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology